Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603066 · ClinicalTrials.gov registry record · Phase 1
Tariquidar-ondansetron Combination in Neuropathic Pain
A Phase 1 study of Neuropathic Pain, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04603066 is a Phase 1 study of Neuropathic Pain that has completed, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04603066, a Phase 1 study of Neuropathic Pain, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study. To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.
Conditions Studied
Interventions
- DRUG Ondansetron 16 mg with Tariquidar
- DRUG Ondansetron 16 mg with Placebo
Study Locations (1)
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-01-31 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603066
The ClinicalTrials.gov registry entry for NCT04603066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (76% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron 16 mg with Tariquidar is the first listed.
NCT04603066 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04603066 about?
NCT04603066 is a clinical study titled "Tariquidar-ondansetron Combination in Neuropathic Pain". Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study. To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.
What is the current status of trial NCT04603066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-01-31. Estimated completion is 2023-11-03.
What conditions does trial NCT04603066 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT04603066?
The interventions under investigation include: Ondansetron 16 mg with Tariquidar (DRUG), Ondansetron 16 mg with Placebo (DRUG).
Who is sponsoring clinical trial NCT04603066?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603066 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Effects of Smoked Marijuana on Neuropathic Pain
COMPLETED · Phase 1
-
Topical Naloxone to Diagnose Ocular Pain
COMPLETED · Phase 1
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.